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Objectives/Hypothesis: To investigate the allelic prevalence of resistance to clarithromycin in the DNA of clinical
isolates of Helicobacter pylori obtained from biopsy specimens of patients with chronic tonsillitis by Scorpion real-time poly-
merase chain reaction (PCR).
Study Design: Pathologic specimens of patients with chronic tonsillitis were used for rapid urease test, and blocks of
paraffin-embedded tonsillar tissue were used for McMullen staining, rapid urease test, and Scorpion real-time PCR test.
Methods: A total of 103 biopsy samples were obtained from patients with chronic tonsillitis and examined for the pres-
ence of clarithromycin resistant H. pylori. Modified McMullen staining and rapid urease test were done on the all the samples.
The DNA of specimens was extracted from the pathology blocks, and Scorpion real-time PCR was performed on a final
volume of 25 lL.
Results: Of 103 biopsy specimens, 22 samples were identified as infected by H. pylori, of which none were sensitive to
clarithromycin. One had the A2143G genotype, and four had the A2142G genotype. Two had a mixed sensitive and the
A2143G genotype, and five had a mixed sensitive and A2142G genotype. One strain had a mixed genotype of sensitive,
A2143G, and A2142G.
Conclusions: The reported rate of resistance to clarithromycin is of great variation among H. pylori strains isolated
from specimens in different countries. Our study showed that the most prevalent genotypes in our H. pylori-positive speci-
mens was A2142G followed by A2143G, which is different from reported results of allele-specific genotyping of H. pylori
strains isolated from gastric biopsy and may be a result of cross-resistance to erythromycin and other macrolides.
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INTRODUCTION
It has been reported that the chronic pharyngitis
might be associated with Helicobacter pylori infection.1–5
Bacterial infections of the tonsils and adenoids are
treated with various antibiotics, and surgical removal is
considered in situations resistant to anti-H. pylori ther-
apy or in frequently recurrent infections.6
So far, numerous studies regarding the determina-
tion of antibiotic resistance in clinical isolates of
H. pylori have been carried out, leading to detection of
antibiotic resistance among different strains of this bac-
terium worldwide.7 The phenomenon of resistance to
metronidazole, amoxicillin, tetracycline, as well as high-
level resistance to clarithromycin have been emphasized
in many previous studies.8 Most studies to determine
the drug resistance have been performed on H. pylori
isolates obtained from adults, and there are little data
regarding the determination of H. pylori antibiotic
resistance in clinical isolates collected from children.
Studies on detection of drug resistance of H. pylori in
Iran have also been limited to a small amount of
research carried out throughout the country.7 Based on
findings of numerous studies,9 it is clear that the
H. pylori resistance against clarithromycin, a key compo-
nent of the triple drug treatment protocol to eradicate
this organism, is considerably high, up to 20% in some
countries. This level of drug resistance against clarithro-
mycin is regarded as a major risk factor for treatment
failure leading to a decrease of more than 70% in effi-
cacy of the first-line drugs.9–11
Falsafi et al.,7 in their study on the Iranian popula-
tion, demonstrated the initial presence of a high level
(25%) of resistance to clarithromycin among clinical
isolates of H. pylori, whereas this antibiotic was unavail-
able in the country at the time of study.
The mechanism of resistance against clarithromycin
by H. pylori is due to a decrease in attachment of this
drug to the bacterial ribosome12 that occurs through
point mutations in the coding region of 23SrRNA for
peptidyl transferase, leading to development of resist-
ance against clarithromycin. There are three major point
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mutations occurring in the vicinity of the 23SrRNA gene
that are responsible for the development of resistance to
clarithromycin in H. pylori.12–14 The most common types
of such mutations are A2142G and A2143G, and the
most unusual one is the A2142C mutation.15 Other rare
mutations discovered so far include T2717C, A213G,
G2141A, and T2182C mutations.16–18 Because the
A213G, G2141A, and T2117C mutations have been
reported only once and there are no other reports of
these mutations in the literature, and as the T2182C
mutation is also seen in clarithromycin-sensitive iso-
lates,16 it seems that these mutations play little role in
the development of resistance against clarithromycin.19
Several techniques of real-time polymerase chain
reaction (PCR) for detection of susceptibility to clarithro-
mycin have been described,20,21 and among these the
Scorpion real-time PCR is reported to have the potential
to accurately differentiate between the diverse alleles of
target nucleotides through a one-step process.22–24
Recently, it has been shown that there is clinically
significant mutation information of isolated clarithromy-
cin resistance of H. pylori. Hansomburana and
colleagues reported that in their studied samples the
most common mutation was A2142G, and it was associ-
ated with high MIC of clarithromycin.25 Abadi and
colleagues reported that high A2143G mutation fre-
quency may increase treatment failure.26
Thus, considering the crucial importance of clari-
thromycin in treatment of H. pylori infections, the
present study attempted to investigate the allelic muta-
tion prevalence of resistance to clarithromycin in clinical
isolates of H. pylori obtained from biopsy specimens of
patients with chronic tonsillitis by Scorpion real-time
PCR.
MATERIALS AND METHODS
This was an experimental study in which 103 biopsy sam-
ples were obtained from patients with chronic tonsillitis who
visited the ear, nose, and throat clinic at Quds Hospital (affili-
ated with Qazvin University of Medical Sciences). These
samples were examined for the presence of H. pylori and to
determine the prevalence of resistance against clarithromycin.
All patients had signs of chronic tonsillitis: sore throat, dyspha-
gia,27 and voice roughness28 of more than 3-months duration.
H. pylori presence was tested by serology, and the patients
studied had no previous history of reflux or gastric disorders.
Pathologic specimens of patients with chronic tonsillitis were
used for rapid urease testing, and blocks of paraffin-embedded
tonsillar tissue were used for McMullen staining and Scorpion
real-time PCR testing.
Modified McMullen’s Staining of Tonsillar
Biopsy
The paraffin-embedded sections was dewaxed, dehydrated,
and covered by carbolfuchsin for 2 minutes. The sections were
rinsed and stained in malachite green for 2 minutes. The slides
were then rinsed in tap water and air dried. Using this proce-
dure, gull-shaped H. pylori were stained magenta against light
green tonsillar tissue.
Rapid Urease Test
The rapid urease test (RUT) was performed using a com-
mercial RUT kit obtained from Cham Enzyme (Tehran, Iran).
For positive control, a standard strain of H. pylori ATCC 26695
was used, and distilled water was employed as a negative
control.
The DNA of specimens was extracted from the pathology
blocks after removal of paraffin from the prepared slice, and
DNA extraction was carried out using a commercial extraction
kit (Roche, Grenzach-Wyhlen, Germany).The DNA content of
specimens was measured using the NanoDrop instrument
(Applied Biosystems, Carlsbad, CA). The final concentration of
DNA following application of the extraction procedure men-
tioned earlier was 200 6 10 ng.
Scorpion Real-Time PCR
The primers used in this study were designed based on a
protocol described by Burucoa et al.,19 in which the target of
amplification was the position of adenine next to the 23SrRNA
gene. The forward primer, 23SF2, is a regular primer located
107 to 125 bases upstream of the adenine. The reverse Scorpion
primers, which are complementary mutations to those that
have to be detected, are designed to end their 30 end in a man-
ner used to design the 30-mismatched reverse primers.10,19 The
primers used in the present study were similar to those used by
Burucoa et al., except for replacing the quencher BHQ1 with
BHQ2 within the 23SscA2142G oligonucleotide. Primers were
purchased from Metabion Company (Martinsried, Germany).
The Scorpion real-time PCR was performed on a final volume of
25 lL consisting of Premix Ex Taq (TaKaRa, Shiga, Japan), 5
lL of extracted DNA from the biopsy specimen or 1 lL of
extracted DNA from culture, 0.1 lM of 23SF2 primer, 0.14 lM
of Scorpion primer 23SscA2142G, 0.18 lM of 23SscA2143G, 0.1
lM of 23SscA2142C, and 0.08 lM of 23SscWT Scorpion pri-
mers.7 Amplification was carried out according to Burucoa
et al.,19 and appropriate modifications were made for use in the
ABI Prism 7500 Sequence Detection System (Applied Biosys-
tems) as follows: denaturation step (95C/3 seconds), followed
by 50 cycles of reactions containing denaturation (95C/3 sec-
onds), annealing (55C/34 seconds), and extension (72C/20
seconds). A positive control of extraction was obtained by the
detection of a fragment of a gene coding for b-hemoglobin by
Scorpion real-time PCR using SYBR green detection canal and
BGLO1 and BGLO2 primers.19
Scorpion real-time PCR positive control. Initially, PCR
was performed on DNA of a standard strain of H. pylori ATCC
26695 and confirmed resistant strains,29 followed by PCR on a
mixture of wild types and mutants to re-examine the ability of
this technique to detect H. pylori.
RESULTS
In our paraffin-embedded study samples, 19 sam-
ples had a positive modified McMullen’s staining result,
and from our 103 samples, 50 samples showed positive
RUT. Of 103 biopsy specimens, 22 samples were identi-
fied as infected by H. pylori by Scorpion real-time PCR
assay, of which nine were sensitive to clarithromycin
(Fig. 1). One had the A2143G genotype, and four had
the A2142G genotype. Two had a mixed sensitive and
A2143G genotype (Fig. 2), and five had mixed sensitive
and A2142G genotypes (Fig. 3). One strain had a mixed
genotype of sensitive, A2143G, and A2142G. Distribution
frequency of genotyped clarithromycin H. pylori strains
are shown in Figure 4.
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Gel electrophoresis of Scorpion real-time PCR prod-
uct is shown in Figure 5. A 140-bp amplicon is indicative
of a successful amplification. Pathological diagnosis of 93
samples (90.3%) from our 103 studied samples was
chronic tonsillitis, and 10 samples (9.7%) had a chronic
tonsillitis plus follicular hypertrophy diagnosis. Our 103
Fig. 1. Amplification plot of samples
infected with sensitive Helicobacter
pylori strains.
Fig. 2. Amplification plot of samples
coinfected with sensitive and
A2143G Helicobacter pylori strains.
Fig. 3. Amplification plot of samples
infected with sensitive and A2142G
Helicobacter pylori strains.
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patients comprised 46 males and 57 females, with a sex
ratio of 1:1.2, respectively. None of our patients were
treated with clarithromycin before admittance for tonsil-
lectomy. Age distribution of our study patients is shown
in Table I.
DISCUSSION
The reported rate of resistance to clarithromycin is
of great variation among H. pylori strains isolated from
gastric biopsy specimens in different countries, as shown
in a study by Ahmad et al., where a resistant rate of
13.2% in H. pylori strains against clarithromycin was
reported.30 In some cases, the studies carried out in dif-
ferent parts of a single country are also indicative of
considerable differences. In their study, Falsafi et al.7
reported the existence of a resistance rate of as high as
25% against clarithromycin, whereas at the time of the
study this drug was not in common use in the country
yet. In another study by Megraud,9 the rate of resistance
to clarithromycin was reported to be around 20%.
In Iran, the study carried out by Falsafi et al.7 indi-
cated that the resistance rate against clarithromycin
was 25%, whereas in another study by Fallahi and Mal-
eknejad31 on 24 cultures positive for H. pylori obtained
from a total of 62 children, the resistance rate was
reported to be approximately 16.4%. In other studies by
Malekzadeh et al.32 and Khashei et al.,33 a resistance
rate of 25.6% against clarithromycin was seen among
the H. pylori strains obtained from gastric biopsy speci-
mens from patients in Isfahan using both culture and
randomly amplified polymorphic DNA-PCR.
In their study, Burucoa and colleagues16 found that
from 60 culture-positive H. pylori specimens, 24 were
clarithromycin resistant, and of these samples 16 had
A2143G, six had A2142G, and two had A2142G. Li and
colleagues34 found in their study that of 13 PCR-positive
H. pylori samples, nine had wild-type genotypes, two
had the A2143 genotype, and one had the A2142G geno-
type. These results do not confirm our results, in which
of 103 specimens we had four A2143G mutants and one
A2143G genotype.
Difference in the prevalence of A2192G genotypes
in isolated bacteria in these studies may originate from
different rates of cross-resistance to other macrolides. It
has been reported that H. pylori strains that are resist-
ant to erythromycin may be resistant to clarithromycin
and vice versa.35 Also, high resistance to erythromycin
was observed in H. pylori strains isolated in Iran.7,36
CONCLUSION
Due to possible cross-resistance that may exist
among macrolides in areas with a high incidence of
erythromycin resistance, the evolutionary pattern of sus-
ceptibility to clarithromycin and other antibiotics must
be accurately considered. On the other hand, significant
coinfection of sensitive and clarithromycin-resistant H.
pylori strains isolated in this study shows that this coin-
fection may be lost in the routine procedures of H. pylori
drug sensitivity evaluation. Application of molecular
methods along with routine antibiogram procedures are
recommended.
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